For decades, cancer therapy research has been deciphered by the isolated analyses of transcriptomics, proteomics, or cell morphology to resolve heterogeneous responses in a series of assays requiring multiple biological samples which limit the ability to capture the full picture of the biological response. Integrating these readouts through multiplexed analysis enables a comprehensive understanding of how gene expression relates to functional outcomes and phenotypic effects, offering a holistic view for research of cellular processes impacted by treatment.
Tyrosine kinase inhibitors (TKIs) have significantly advanced the treatment of non-small cell lung cancer (NSCLC) yet achieving consistent and durable patient responses remains a challenge. Here, we utilized AVITI24™, a platform that enables spatial co-detection of RNA, protein, phospho-proteins, and cell morphology at subcellular resolution within a single biological sample to resolve complex systemic responses to TKIs. By consolidating multiomic data in a single assay, this platform facilitates the resolution of multidimensional mechanisms underlying tumor responsiveness and drug resistance. By bridging molecular and morphology insights, our study provides a powerful framework for studying the intricate dynamics of targeted therapies in NSCLC, paving the way for innovative strategies to enhance cancer treatment and personalize patient care.